Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Baselga

Showing results (91-100 of 168) with videos related to

Pageof 17
Sort By:
Differentiation; Research in Biological Diversity|January 1, 1994
All-trans-retinoic acid and hexamethylene bisacetamide (HMBA) regulate TGF-alpha and Hst-1/kFGF expression in differentiation sensitive but not in resistant human teratocarcinomasW H Miller, W J Maerz, J Kurie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1995
Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cellsF Ciardiello, V Damiano, C Bianco, et al.
Seminars in Oncology|December 1, 1995
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodesC A Hudis, A D Seidman, J Baselga, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 1996
Expression of the fructose transporter GLUT5 in human breast cancerS P Zamora-León, D W Golde, I I Concha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II studyE Felip, R Rosell, M Domine, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2000
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancerJ Bellmunt, V Guillem, L Paz-Ares, et al.
Oncogene|October 27, 2009
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthS Chandarlapaty, M Scaltriti, P Angelini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensityA Ribas, J Albanell, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2013
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trialC Criscitiello, H A Azim, D Agbor-tarh, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 17, 2011
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) studyV Semiglazov, W Eiermann, M Zambetti, et al.
Pageof 17

Showing results (91-100 of 168) with videos related to

Sort By:
Pageof 17
Differentiation; Research in Biological Diversity|January 1, 1994
All-trans-retinoic acid and hexamethylene bisacetamide (HMBA) regulate TGF-alpha and Hst-1/kFGF expression in differentiation sensitive but not in resistant human teratocarcinomasW H Miller, W J Maerz, J Kurie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1995
Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cellsF Ciardiello, V Damiano, C Bianco, et al.
Seminars in Oncology|December 1, 1995
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodesC A Hudis, A D Seidman, J Baselga, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 1996
Expression of the fructose transporter GLUT5 in human breast cancerS P Zamora-León, D W Golde, I I Concha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II studyE Felip, R Rosell, M Domine, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2000
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancerJ Bellmunt, V Guillem, L Paz-Ares, et al.
Oncogene|October 27, 2009
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthS Chandarlapaty, M Scaltriti, P Angelini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensityA Ribas, J Albanell, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2013
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trialC Criscitiello, H A Azim, D Agbor-tarh, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 17, 2011
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) studyV Semiglazov, W Eiermann, M Zambetti, et al.
Pageof 17